search
Back to results

Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma

Primary Purpose

Pancreatic Carcinoma, Laparoscopic, Pancreaticoduodenectomy

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
TLPD Surgery
OPD Surgery
Sponsored by
Tongji Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatic Carcinoma focused on measuring Pancreatic Carcinoma, Laparoscopic, Pancreaticoduodenectomy, Survival

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age between 18 years and 75 years.
  2. Histologically confirmed PDAC or clinically diagnosed PDAC by an MDT without histopathologic evidence.
  3. Patients feasible to undergo both LPD and OPD according to MDT evaluations.
  4. Patients understanding and willing to comply with this trial.
  5. Provision of written informed consent before patient registration.
  6. Patients meeting the curative treatment intent in accordance with clinical guidelines.

Exclusion Criteria:

  1. Patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.
  2. Patients requiring left, central or total pancreatectomy or other palliative surgery.
  3. Preoperative American Society of Anaesthesiologists (ASA) score ≥ 4.
  4. History of other malignant disease.
  5. Pregnant or breast-feeding women.
  6. Patients with serious mental disorders.
  7. Patients treated with neoadjuvant therapy.
  8. Patients with vascular invasion and requiring vascular resection as evaluated by the MDT team according to abdominal imaging data.
  9. Body mass index > 35 kg/m2.
  10. Patients participating in any other clinical trials within 3 months.

Sites / Locations

  • Department of Biliary and Pancreatic Surgery, Tongji Hospital, Affiliated Tongji Medical College, Huazhong University of Science and TechnologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

TLPD

OPD

Arm Description

Total laparoscopic pancreaticoduodenectomy for pancreatic cancer

Open pancreaticoduodenectomy for pancreatic cancer

Outcomes

Primary Outcome Measures

5-year overall survival
5-year overall survival

Secondary Outcome Measures

overall survival
the interval between the day of surgery and the day of death for various reasons
disease-free survival
the interval between the day of surgery and the day of tumour recurrence
90-day mortality
the percentage of patients who died within 90 days postoperatively
complication rate
complications related to PD
comprehensive complication index
calculated as the sum of all complications that are weighted for their severity
length of stay
the number of nights spent in the hospital from the end of the surgical procedure until discharge or death
intraoperative indicators
description of the patients' intraoperative condition relating to the safety of patients

Full Information

First Posted
December 20, 2018
Last Updated
February 27, 2022
Sponsor
Tongji Hospital
Collaborators
Shandong Provincial Hospital, The Second Hospital of Hebei Medical University, The Affiliated Hospital of Xuzhou Medical University, Xinqiao Hospital of Chongqing, Hunan Provincial People's Hospital, The First Hospital of Jilin University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The Third Affiliated Hospital of Soochow University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of North Sichuan Medical College, First Affiliated Hospital of Chongqing Medical University, Peking Union Medical College Hospital, Henan Provincial People's Hospital, Sir Run Run Shaw Hospital, Fujian Medical University Union Hospital, Fudan University
search

1. Study Identification

Unique Protocol Identification Number
NCT03785743
Brief Title
Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma
Official Title
Total Laparoscopic Pancreaticoduodenectomy Versus Open Pancreaticoduodenectomy for Pancreatic Carcinoma(TJDBPS07) a Multicenter Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2019 (Actual)
Primary Completion Date
March 1, 2027 (Anticipated)
Study Completion Date
May 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tongji Hospital
Collaborators
Shandong Provincial Hospital, The Second Hospital of Hebei Medical University, The Affiliated Hospital of Xuzhou Medical University, Xinqiao Hospital of Chongqing, Hunan Provincial People's Hospital, The First Hospital of Jilin University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The Third Affiliated Hospital of Soochow University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of North Sichuan Medical College, First Affiliated Hospital of Chongqing Medical University, Peking Union Medical College Hospital, Henan Provincial People's Hospital, Sir Run Run Shaw Hospital, Fujian Medical University Union Hospital, Fudan University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background: Pancreatic cancer (PC) is one of the most aggressive malignant neoplasms with poor outcomes. Pancreatoduodenectomy (PD) is the only curative treatment for PC. Minimally invasive surgery has been progressively developed, first with the advent of hybrid-laparoscopy and recently with the total laparoscopy surgeries, but a number of issues are currently being debated, including the superiority between total laparoscopic pancreaticoduodenectomy (TLPD)and the open pancreaticoduodenectomy (OPD). Studies comparing these two surgery techniques are merging and randomized controlled trials (RCT) are lacking but clearly required. Methods/design: TJDBPS07 is a multicenter prospective, randomized controlled, trial comparing TLPD and OPD in pancreatic cancers. A total of 200 patients with pancreatic cancer underwent PD will be randomly allocated to the TLPD group or OPD group with an enhanced recovery after surgery (ERAS) pattern. The trial's aim is to exploring the overall survival (OS), disease free survival (DFS) and quality of life. The duration of the entire trial is seven years including prearrangement, a presumably five-year follow-up and analyses. Discussion: Despite the fact there are several RCTs comparing minimally invasive pancreaticoduodenectomy (MIPD) and Open approach or LPD versus OPD. This trial will be the first comparing TLPD and OPD in a large multicenter setting. TJDBPS01 trial is hypothesized to assess whether TLPD has superiority over OPD in recovery and other aspects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Carcinoma, Laparoscopic, Pancreaticoduodenectomy
Keywords
Pancreatic Carcinoma, Laparoscopic, Pancreaticoduodenectomy, Survival

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TLPD
Arm Type
Experimental
Arm Description
Total laparoscopic pancreaticoduodenectomy for pancreatic cancer
Arm Title
OPD
Arm Type
Experimental
Arm Description
Open pancreaticoduodenectomy for pancreatic cancer
Intervention Type
Procedure
Intervention Name(s)
TLPD Surgery
Intervention Description
TLPD
Intervention Type
Procedure
Intervention Name(s)
OPD Surgery
Intervention Description
OPD
Primary Outcome Measure Information:
Title
5-year overall survival
Description
5-year overall survival
Time Frame
5 year
Secondary Outcome Measure Information:
Title
overall survival
Description
the interval between the day of surgery and the day of death for various reasons
Time Frame
5 years
Title
disease-free survival
Description
the interval between the day of surgery and the day of tumour recurrence
Time Frame
5 years
Title
90-day mortality
Description
the percentage of patients who died within 90 days postoperatively
Time Frame
90 days
Title
complication rate
Description
complications related to PD
Time Frame
90 days
Title
comprehensive complication index
Description
calculated as the sum of all complications that are weighted for their severity
Time Frame
90 days
Title
length of stay
Description
the number of nights spent in the hospital from the end of the surgical procedure until discharge or death
Time Frame
90 days
Title
intraoperative indicators
Description
description of the patients' intraoperative condition relating to the safety of patients
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 18 years and 75 years. Histologically confirmed PDAC or clinically diagnosed PDAC by an MDT without histopathologic evidence. Patients feasible to undergo both LPD and OPD according to MDT evaluations. Patients understanding and willing to comply with this trial. Provision of written informed consent before patient registration. Patients meeting the curative treatment intent in accordance with clinical guidelines. Exclusion Criteria: Patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs. Patients requiring left, central or total pancreatectomy or other palliative surgery. Preoperative American Society of Anaesthesiologists (ASA) score ≥ 4. History of other malignant disease. Pregnant or breast-feeding women. Patients with serious mental disorders. Patients treated with neoadjuvant therapy. Patients with vascular invasion and requiring vascular resection as evaluated by the MDT team according to abdominal imaging data. Body mass index > 35 kg/m2. Patients participating in any other clinical trials within 3 months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Renyi Qin
Phone
+8602783665314
Email
172356995@qq.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hag Zhang
Phone
+8602783665314
Email
172356995@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Renyi Qin
Organizational Affiliation
Tongji Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Biliary and Pancreatic Surgery, Tongji Hospital, Affiliated Tongji Medical College, Huazhong University of Science and Technology
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430030
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Junfang O Zhao, MD, PhD
Phone
+8615827539076
Email
zhaojunfang2012@hotmail.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35379633
Citation
Pan S, Qin T, Yin T, Yu X, Li J, Liu J, Zhao W, Chen X, Li D, Liu J, Li J, Liu Y, Zhu F, Wang M, Zhang H, Qin R; Minimally Invasive Treatment Group in the Pancreatic Disease Branch of China's International Exchange and Promotion Association for Medicine and Healthcare (MITG-P-CPAM). Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial. BMJ Open. 2022 Apr 4;12(4):e057128. doi: 10.1136/bmjopen-2021-057128.
Results Reference
derived

Learn more about this trial

Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma

We'll reach out to this number within 24 hrs